The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system
Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.
To order this 250+ page report, which features 140+ figures and 170+ tables, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:
- Target Disease Indication
- Cancer
- Genetic Disorders
- Neurological Indications
- Others
- Route of Administration
- Oral
- Inhalation
- Key Geographies
- North America
- Europe
Asia-Pacific and the Rest of the World
The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:
- GW Pharmaceuticals
- Corbus Pharmaceuticals
- Tilray
- Tetra Bio-Pharma
- Botanix Pharmaceuticals
- Kalytera Therapeutics
- Therapix Biosciences
- Echo Pharmaceuticals
- Avicanna
- GB Sciences
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
5. COMPANY PROFILES
6. ACADEMIC GRANTS ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. MERGERS AND ACQUISITIONS
9. DRUG DEVELOPMENT STRATEGY ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
